U.S. OPPORTUNISTIC VALUE

OVERVIEW

The GMO U.S. Opportunistic Value Fund (the "Fund") seeks to generate total return by investing primarily in U.S. equities. The Fund measures its performance against the MSCI U.S. Value Index.

GMO's U.S. Opportunistic Value Fund seeks to profit from our Asset Allocation Team's top-down insights as to the most attractively valued segment of the U.S. market. Currently, the team finds "deep value" (cheapest 20%) stocks to be truly dislocated in the U.S. This actively managed Fund avoids the "shallow value" stocks, which are expensive relative to their own history, and focuses solely on the deep value names. With this Fund we focus on the U.S. stocks that GMO's Systematic Equity team identifies as the most undervalued, recognizing that relying on reported financials and index definitions of value can lead investors to misjudge the opportunity.

FACTS

Share Class	Class VI
Share Class Ticker	UUOAX
Share Class Inception	13-Dec-22
Fund Inception	13-Dec-22
Total Assets	$279mm USD
Index	MSCI USA Value (Gross)
Alternate Index	MSCI USA (Gross)

CUMULATIVE TOTAL RETURNS (USD, NET OF FEES, %)

	MTD	QTD	YTD	2025	2024	2023	2022
Class VI	5.59	5.59	23.15	14.93	13.09	16.45	-3.36
Index	3.52	3.52	19.18	13.71	14.34	9.24	-2.41
Alternate Index	-0.97	-0.97	11.54	17.75	25.08	27.10	-4.50

ANNUALIZED TOTAL RETURNS (USD, NET OF FEES, %)

	1 Year	3 Years	5 Years	10 Years	ITD
Class VI	30.00	22.54	-	-	16.37
Index	22.21	20.56	-	-	13.80
Alternate Index	11.58	23.47	-	-	19.45

STANDARDIZED SEC RETURNS (USD, NET OF FEES, %)(AS OF 30-SEP-26)

	1 Year	3 Years	5 Years	10 Years	ITD
Class VI	22.03	18.89	-	-	15.10
Index	16.95	18.03	-	-	13.09
Alternate Index	15.35	22.91	-	-	20.24

RISK PROFILE (SINCE INCEPTION 30-DEC-22)

Alpha (Jensen's)	2.54
Beta	1.04
R Squared	0.88
Sharpe Ratio	0.98
Standard Deviation	13.13

ANNUAL EXPENSES (%)

Net Expense Ratio	0.40
Gross Expense Ratio	0.45

Net Expense Ratio reflects the reduction of expenses from fee reimbursements. The fee reimbursements will continue until at least 30 June 2027. Elimination of this reimbursement will result in higher fees and lower performance.
Gross Expense Ratio is equal to the Fund's Total Annual Operating Expenses set forth in the Funds most recent prospectus dated 30 June, 2026.

Net of all fees and expenses after reimbursement by the Manager, but not transaction costs, if any. If certain expenses were not reimbursed, performance would be lower. **Performance data quoted represents past performance and is not indicative of future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance data may be lower or higher than the performance data provided herein. To obtain performance information to the most recent month-end, visit www.gmo.com.** The portfolio is actively-managed, is not managed relative to a benchmark and uses an index for performance comparison purposes only and, where applicable, to compute a performance fee. The Index used for performance reporting purposes changed from S&P Composite 1500 to MSCI U.S.A. Value effective June 30th, 2024.

Risks: Risks associated with investing in the Fund may include: (1) Focused Investment Risk: the Fund invests its assets in the securities of a limited number of issuers, and a decline in the market price of a particular security held by the Fund may affect the Fund's performance more than if the Fund invested in the securities of a larger number of issuers; (2) Commodities Risk: commodity prices can be extremely volatile, and exposure to commodities can cause the value of the Fund's shares to decline or fluctuate more than if the Fund had a broader range of investments; and (3) Market Risk - Equities: the market price of equities may decline due to factors affecting the issuer, its industries, or the economy and equity markets generally. Declines in stock market prices generally are likely to reduce the net asset value of the Fund's shares. For a more complete discussion of these and other risks, please consult the Fund's Prospectus. **Performance Returns:** Returns shown for periods greater than one year are on an annualized basis. Annualized Returns may include the impact of purchase premiums and redemption fees. The GMO Trust funds are distributed in the United States by Funds Distributor LLC. GMO and Funds Distributor LLC are not affiliated.

PORTFOLIO MANAGEMENT



George Sakoulis
Joined GMO in 2020
MA & PhD, University of Washington



Warren Chiang, CFA
Joined GMO in 2015
MBA, University of California, Berkeley



John Thorndike
Joined GMO in 2015
BA, Bowdoin College

U.S. OPPORTUNISTIC VALUE

CHARACTERISTICS

	Portfolio	Index
Price/Earnings - Forecast 1 Yr Wtd Mdn	13.2x	18.6x
Price/Earnings - Hist 1 Yr Wtd Mdn	17.3x	23.2x
Price/Book - Hist 1 Yr Wtd Avg	2.5x	3.6x
Price/Cash Flow - Hist 1 Yr Wtd Mdn	11.1x	16.2x
Return on Equity - Hist 1 Yr Mdn	16.1%	19.4%
Debt/Equity - Wtd Mdn	0.7x	0.6x
Market Cap - Wtd Mdn Bil	123.6 USD	187.5 USD
Number of Equity Holdings	164	372
Active Share	57.2%	N/A

SECTORS (%)

Sector	Portfolio	Index
Communication Services	10.9	6.3
Consumer Discretionary	8.7	4.0
Consumer Staples	7.0	7.5
Energy	10.9	7.2
Financials	22.7	18.6
Health Care	18.2	13.9
Industrials	4.8	10.0
Information Technology	14.9	23.2
Materials	1.6	3.0
Real Estate	0.3	2.6
Utilities	0.1	3.6

MARKET CAP BAND EXPOSURES ($B)

	Portfolio	Index
Small (5.6 & Below)	4.6	0.0
Small - Medium (5.6 To 20.6)	9.3	3.4
Medium (20.6 To 52.7)	11.6	14.0
Medium - Large (52.7 To 155.0)	31.7	25.3
Large (155.0 & Above)	42.8	57.3

TOP HOLDINGS

Company	Sector	%
Microsoft Corp	Information Technology	7.2
Meta Platforms Inc	Communication Services	4.7
ExxonMobil Holdings Corp	Energy	4.3
JPMorgan Chase & Co	Financials	2.8
Merck & Co Inc	Health Care	2.6
Pfizer Inc	Health Care	2.5
Verizon Communications Inc	Communication Services	2.3
Bristol-Myers Squibb Co	Health Care	2.0
Regeneron Pharmaceuticals Inc	Health Care	1.9
Progressive Corp/The	Financials	1.7
Total		**32.0**

U.S. OPPORTUNISTIC VALUE

IMPORTANT INFORMATION

An investor should consider the fund's investment objectives, risks, charges and expenses before investing. This and other important information can be found in the funds prospectus. To obtain a prospectus please visit www.gmo.com. Read the prospectus carefully before investing.

Index(es): The MSCI USA Value (Gross) Index is an independently maintained and widely published index comprised of large and mid cap US securities exhibiting overall value style characteristics. MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder. Please visit https://www.gmo.com/americas/benchmark-disclaimers/ to review the complete benchmark disclaimer notice.The MSCI USA (Gross) Index is an independently maintained and widely published index comprised of large and mid cap segments of the US market. MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder. Please visit https://www.gmo.com/americas/benchmark-disclaimers/ to review the complete benchmark disclaimer notice.

The GMO Trust funds are distributed in the United States by Funds Distributor LLC. GMO and Funds Distributor LLC are not affiliated.

GLOSSARY

Risk Statistics: Risk profile data is net of fees. Alpha is a measure of risk-adjusted return. Beta is a measure of a portfolio's sensitivity to the market. R-Squared is a measure of how well a portfolio tracks the market. Sharpe Ratio is the return over the risk free rate per unit of risk. Std Deviation is a measure of the volatility of a portfolio.
Sector Exposures: The Global Industry Classification Standard (GICS) is the exclusive intellectual property of MSCI Inc. (MSCI) and Standard & Poor's, a division of The McGraw-Hill Companies, Inc. (S&P). Neither MSCI, S&P, nor any third party makes any representations or warranties, express or implied, with respect to GICS or the results to be obtained by the use thereof, and expressly disclaim all warranties, including of merchantability and fitness for a particular purpose. Neither MSCI, S&P, nor any third party shall have any liability for any damages of any kind relating to the use of GICS. **Top Holdings:** Portfolio holdings are percent of equity. Where applicable, the top holdings are derived by looking through to the underlying funds in which the asset allocation funds invest and, where appropriate, individual security positions are aggregated. They are subject to change and should not be considered a recommendation to buy individual securities.
Please refer to https://www.gmo.com/americas/glossary-of-terms/ for additional portfolio characteristic definitions.

ABOUT GMO

Founded in 1977, GMO is a global asset manager committed to delivering superior performance and advice to our clients. We are privately owned, which allows us to singularly focus on our sole business – achieving outstanding long-term client investment outcomes. Offering multi-asset, equity, fixed income, and alternative strategies, we invest with a long-term, valuation-based philosophical approach.

AMSTERDAM | BOSTON | LONDON | SAN FRANCISCO* | SINGAPORE | SYDNEY | TOKYO**

*GMO's West Coast Hub is comprised of members of Investment, Global Client Relations, and other teams located in and around the Greater San Francisco area
**Representative Office